Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer

Cancer

Gynaecological

17 February 2025

Published on 13 Sep 2024
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

Dostarlimab 500 mg concentrate for solution for infusion, in combination with carboplatin and paclitaxel, followed by dostarlimab as monotherapy for untreated mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.

Funding status

Dostarlimab 500 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2025.

Clinical indications, subsidy class and MediShield Life claim limits for dostarlimab are provided in the Annex.

Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer (Updated 17 Feb 2025) [PDF, 223 KB]

PES Dostarlimab for treating primary advanced or recurrent endometrial cancer (Updated 17 Feb 2025) [PDF, 55 KB]